SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX

NEW YORK, Sept. 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX).   Such investors are advised to contact Robert S. Willoughby at  newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether TG Therapeutics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 8, 2023, citing data from Symphony Health, Cantor Fitzgerald stated that the Company's sales of the multiple sclerosis therapy Briumvi for August 2023 had reached $7.2 million, up from $5.9 million in July, but that September sales for Briumvi will need to be strong in order for the Company to meet consensus estimates. 

On this news, TG Therapeutics' stock price fell $0.90 per share, or 7.97%, to close at $10.39 per share on September 8, 2023.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.

CONTACT:
Robert S. Willoughby
Pomerantz LLP  
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-tg-therapeutics-inc---tgtx-301926709.html

SOURCE Pomerantz LLP